29.15
12-May-25 14:33:11
15 minutes delayed
Stocks
+1.83
+6.70%
Today's range
28.18 - 29.39
ISIN
N/A
Source
NASDAQ
Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021
11 Feb 2021 07:00:01 By Nasdaq GlobeNewswire
Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused
26 Jan 2021 16:01:00 By Nasdaq GlobeNewswire
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
17 Jan 2021 10:00:00 By Nasdaq GlobeNewswire
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
11 Jan 2021 07:00:01 By Nasdaq GlobeNewswire